
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing growth in its Auryon product line, which is expanding its customer base in both the office-based lab (OBL) and hospital settings, significantly benefiting average selling prices (ASP). The company is also on track to enhance its gross margins, currently reported at 52.5%, through improved manufacturing initiatives and a favorable shift towards higher Med-Tech revenues, with completion anticipated by January 2026. Furthermore, management suggests that continued customer acquisition, increasing utilization within existing accounts, and successful pricing strategies will support ongoing growth for key product offerings.
Bears say
AngioDynamics Inc is anticipating $4 million to $6 million in tariff-related headwinds, which could negatively impact future financial performance. Furthermore, the company expects inventory pressure in the second half of fiscal 2026 due to rising raw material costs, which may strain margins and overall profitability. These factors, alongside reliance on capital sales to drive future disposable demand, suggest an unstable outlook for the company's financial stability.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares